dbp7 Antibody

What is DBP7 and why are antibodies against it important for research?

DBP7 (DEAD-box protein 7) is an ATP-dependent RNA helicase required for 60S ribosomal subunit biogenesis. It functions by regulating the dynamic base-pairing between the snR190 small nucleolar RNA and ribosomal RNA precursors within early pre-60S ribosomal particles . Antibodies against DBP7 are crucial research tools for:

• Visualizing cellular localization of DBP7 through immunofluorescence microscopy

• Studying protein-protein interactions via co-immunoprecipitation experiments

• Monitoring DBP7 expression levels by Western blotting

• Investigating DBP7's association with pre-ribosomal complexes

These applications help researchers understand the fundamental role of DBP7 in ribosome assembly and RNA processing mechanisms.

Which species-specific DBP7 antibodies are available for research?

Research-grade DBP7 antibodies are available for various yeast species, including:

All these antibodies are typically produced in rabbits as polyclonal antibodies and purified through antigen-affinity methods .

What are the typical applications for DBP7 antibodies in ribosome biogenesis research?

DBP7 antibodies are instrumental in multiple experimental approaches to study ribosome biogenesis:

• Western blotting: For detecting DBP7 in whole cell extracts or sucrose gradient fractions to analyze its association with pre-ribosomal particles

• Immunoprecipitation: To isolate DBP7-containing complexes and analyze associated pre-rRNAs and proteins

• Immunofluorescence microscopy: To determine the subcellular localization of wild-type and mutant DBP7 proteins

• ChIP assays: To study potential interactions between DBP7 and chromatin regions containing ribosomal genes

• Co-IP experiments: To investigate protein-protein interactions between DBP7 and other assembly factors

These applications have revealed DBP7's enrichment in fractions containing pre-60S complexes and its association with early pre-ribosomal particles containing 27SA pre-rRNA .

How can DBP7 antibodies help elucidate the role of N- and C-terminal domains in ribosome biogenesis?

DBP7 contains variable N- and C-terminal extensions that flank a conserved helicase core region. Research using domain-specific antibodies can help understand the distinct functions of these domains:

Methodological approach:

• Generate truncated DBP7 proteins (ΔN10, ΔN162, ΔNLS, ΔC694-742, ΔC636-742) with HA tags

• Use anti-HA antibodies to:

  • Assess protein expression via Western blotting

  • Track subcellular localization through immunofluorescence microscopy

  • Perform immunoprecipitation to analyze interactions with pre-rRNAs

  • Monitor association with pre-ribosomal particles via sucrose gradient centrifugation

Research findings demonstrate that:

• The N-terminal domain contains a bipartite nuclear localization signal (NLS) essential for efficient nuclear import

• Removal of this NLS (residues V48-S78) impairs but doesn't completely abolish nuclear import

• Both N- and C-terminal domains are required for normal growth and 60S subunit synthesis

• Truncations affect the stability of DBP7's association with pre-ribosomal particles in immunoprecipitation conditions

This approach allows researchers to characterize the functional roles of different DBP7 domains in ribosome biogenesis.

What strategies can resolve contradictory data between sucrose gradient and immunoprecipitation experiments when studying DBP7 interactions?

A common challenge in DBP7 research is reconciling seemingly contradictory data between different experimental approaches:

Problem: Studies have shown that truncation mutations (ΔN162 and ΔC636-742) don't substantially decrease DBP7's association with pre-60S particles in sucrose gradient experiments but significantly impair this association in immunoprecipitation experiments .

Methodological solutions:

• Comparative analysis using multiple techniques:

  • Perform both sucrose gradient centrifugation and immunoprecipitation

  • Compare results under varying salt and detergent conditions

  • Use cross-linking approaches to stabilize transient interactions

• Quantitative assessment:

  • Conduct quantitative Western blotting to measure the ratio of DBP7 in different complexes

  • Use gradient fractionation followed by mass spectrometry to quantify associated proteins

  • Employ ratiometric analysis comparing DBP7 to control proteins

• Alternative approaches:

  • Implement proximity labeling techniques (BioID or APEX)

  • Utilize structural approaches (cryo-EM) to visualize interactions directly

  • Apply FRET-based assays to monitor protein-protein associations in vivo

The discrepancy likely reflects the different physicochemical constraints imposed by these techniques—immunoprecipitation exposes complexes to harsher conditions (higher salt, detergents, physical pulldown) that may disrupt weaker interactions .

How can DBP7 antibodies be used to investigate the ATP-dependent remodeling activity in pre-ribosomal particles?

DBP7's ATP-dependent helicase activity is crucial for its function in ribosome biogenesis. Researchers can use antibodies to study this activity:

Experimental design:

• Comparative analysis of wild-type vs. catalytically inactive DBP7:

  • Generate strains expressing wild-type DBP7 or catalytically inactive mutant (K197A)

  • Use antibodies to immunoprecipitate these variants and their associated complexes

  • Analyze the co-immunoprecipitated RNAs (pre-rRNAs and snoRNAs) by Northern blotting

  • Compare protein composition by mass spectrometry

• ATP-dependent remodeling assays:

  • Isolate DBP7-containing pre-ribosomal complexes using antibodies

  • Subject the complexes to in vitro remodeling with or without ATP

  • Analyze structural changes by:

    • Chemical probing techniques

    • RNase protection assays

    • Native gel electrophoresis

• Time-resolved experiments:

  • Use DBP7 antibodies to isolate pre-ribosomal particles at different time points after induction

  • Monitor the sequential association/dissociation of factors like the Npa1 complex and snoRNAs

  • Track the recruitment of uL3 which is critical for PTC formation

Research indicates that DBP7 regulates the release of snR190 snoRNP and the Npa1 complex from early pre-60S particles, allowing incorporation of uL3 to stabilize domain I and VI interactions . In the absence of DBP7 or its catalytic activity, early pre-ribosomal particles are targeted for degradation .

What are the optimal conditions for using DBP7 antibodies in immunoprecipitation experiments?

Successful immunoprecipitation with DBP7 antibodies requires careful optimization:

Recommended protocol:

• Preparation of cell extracts:

  • Harvest yeast cells at OD600 of 0.8-1.0

  • Lyse cells using glass beads in buffer containing 50 mM Tris-HCl pH 7.5, 100-150 mM NaCl, 5 mM MgCl2, 0.1% NP-40, and protease inhibitors

  • Clarify lysate by centrifugation at 16,000 × g for 10 min at 4°C

• Immunoprecipitation conditions:

  • For tagged DBP7, use anti-tag agarose beads (e.g., EZview™ Red Anti-HA Affinity Gel)

  • For endogenous DBP7, couple purified antibodies to Protein G Sepharose

  • Incubate lysate with antibody-conjugated beads for 2-3 hours at 4°C with gentle rotation

  • Wash 4-5 times with lysis buffer

• Analysis of co-precipitated components:

  • For RNA analysis, extract RNA using TRIzol and perform Northern blotting

  • For protein analysis, elute bound proteins with SDS sample buffer and perform Western blotting

  • For comprehensive protein identification, use mass spectrometry

Critical considerations:

• Salt concentration affects the stability of DBP7 interactions with pre-ribosomal particles

• Truncation mutations like ΔN162 and ΔC636-742 reduce the stability of these interactions in immunoprecipitation conditions

• Pre-clearing lysates with non-immune IgG can reduce background

• RNase inhibitors should be included if RNA analysis is planned

How can researchers optimize Western blotting protocols for detecting different DBP7 variants?

Detecting DBP7 and its variants by Western blotting requires specific considerations:

Optimized protocol:

• Sample preparation:

  • Extract total proteins using TCA precipitation or direct lysis in SDS sample buffer

  • For sucrose gradient fractions, precipitate proteins with TCA before resuspension

• Gel electrophoresis considerations:

  • Use 8-10% SDS-PAGE gels for full-length DBP7 (~80 kDa)

  • For truncated variants, adjust acrylamide percentage accordingly:

    • ΔC636-742 and ΔC694-742: 10% gels

    • ΔN162: 12% gels

• Transfer and detection:

  • Transfer proteins to PVDF membranes at 100V for 1 hour or 30V overnight

  • Block with 5% non-fat milk in TBST for 1 hour

  • For tagged DBP7, use appropriate anti-tag antibodies (anti-HA, anti-TAP, anti-GFP)

  • For endogenous DBP7, use specific anti-DBP7 antibodies (1:1000-1:5000 dilution)

  • Wash with TBST and detect using appropriate secondary antibodies and chemiluminescence

• Controls and normalization:

  • Include Pgk1 detection as a loading control

  • For nuclear/nucleolar proteins, consider Nhp2 as a compartment-specific control

When analyzing sucrose gradient fractions, consistent Western blotting conditions are essential for comparing the distribution of different DBP7 variants across the gradient.

What methodological approaches can be used to study the interaction between DBP7 and specific rRNA domains using antibodies?

Investigating DBP7's interaction with specific rRNA domains requires specialized techniques:

Recommended methodological approaches:

• Crosslinking and immunoprecipitation (CLIP):

  • UV crosslink cells to stabilize RNA-protein interactions

  • Immunoprecipitate DBP7 using specific antibodies

  • Extract, fragment and sequence associated RNAs

  • Map binding sites to domain V/VI of 25S rRNA

• RNA immunoprecipitation followed by structure probing:

  • Immunoprecipitate DBP7-RNA complexes

  • Perform structure probing (SHAPE, DMS) on associated pre-rRNAs

  • Compare structural patterns between wild-type and mutant strains

• Proximity-based RNA mapping:

  • Express DBP7 fused to a proximity labeling enzyme (APEX2)

  • Activate the enzyme to label nearby RNAs

  • Immunoprecipitate DBP7 and identify labeled RNAs

  • Map proximity sites on the pre-rRNA

• Domain-specific functional validation:

  • Generate rRNA mutants in predicted binding regions

  • Analyze effects on DBP7 association using immunoprecipitation

  • Monitor pre-rRNA processing using Northern blotting

  • Assess ribosome synthesis through polysome profiling

Research has revealed that DBP7 binds specifically to domain V/VI of 25S rRNA, close to the binding site of uL3 in early pre-60S particles . This binding is critical for proper ribosome assembly as it enables the release of snoRNAs and assembly factors, allowing incorporation of uL3 to stabilize domain I and VI interactions .

How can researchers address non-specific binding issues with DBP7 antibodies?

Non-specific binding can complicate the interpretation of DBP7 antibody experiments. Here are methodological approaches to improve specificity:

Troubleshooting procedures:

• Antibody validation:

  • Compare results using different DBP7 antibodies or epitope tags

  • Include a negative control (Δdbp7 strain) to identify non-specific bands

  • Perform peptide competition assays to confirm specificity

• Optimization of immunoblotting conditions:

  • Increase blocking time and concentration (5-10% milk/BSA)

  • Optimize antibody dilution (perform titration experiments)

  • Include detergents (0.1-0.5% Triton X-100) in washing buffers

  • Test different blocking agents (milk vs. BSA)

• Immunoprecipitation optimization:

  • Increase stringency of wash buffers (150-300 mM NaCl)

  • Pre-clear lysates with Protein A/G beads

  • Use crosslinking to stabilize specific interactions

  • Perform sequential immunoprecipitation for higher purity

• Experimental controls:

  • Include isotype control antibodies

  • Use tagged DBP7 variants with highly specific anti-tag antibodies

  • Compare results between purified antibodies and crude sera

Researchers have successfully used HA-tagged DBP7 variants and anti-HA antibodies to minimize non-specific binding issues in immunoprecipitation experiments .

What strategies can researchers employ when DBP7 antibodies fail to detect mutant variants?

Detection of DBP7 mutants can be challenging due to structural changes, expression levels, or stability issues:

Methodological solutions:

• Alternative detection approaches:

  • Add epitope tags to mutant variants (HA, GFP, TAP)

  • Use multiple antibodies targeting different regions of DBP7

  • Enrich proteins by subcellular fractionation before detection

  • Employ mass spectrometry for identification

• Optimization for low-abundance variants:

  • Increase sample loading (2-4× standard amount)

  • Use high-sensitivity detection reagents (ECL Plus, fluorescent secondaries)

  • Concentrate proteins through immunoprecipitation before analysis

  • Enhance extraction with specialized buffers for nuclear proteins

• Stabilization approaches:

  • Include proteasome inhibitors during extract preparation

  • Reduce time and temperature during sample processing

  • Use chemical crosslinking to stabilize protein complexes

  • Express from stronger promoters if expression is the issue

Studies have shown that certain truncations of DBP7 affect protein stability and detection levels. For example, the HA-Dbp7ΔC694-742 variant shows reduced detection in Western blotting, suggesting potential instability of this protein . In such cases, researchers should consider analyzing mRNA levels to determine if the issue is at the translational or post-translational level.

How can researchers resolve conflicting data on DBP7 localization between antibody-based methods and GFP fusion approaches?

Discrepancies between different localization methods require careful analysis and methodological adjustments:

Reconciliation strategies:

• Comparative analysis:

  • Perform side-by-side immunofluorescence and GFP visualization

  • Use multiple fixation methods to rule out fixation artifacts

  • Include co-localization with known compartment markers

  • Quantify distribution patterns across multiple cells

• Technical optimizations:

  • For immunofluorescence, test different fixation methods (formaldehyde, methanol)

  • For GFP fusions, vary the position of the tag (N- or C-terminal)

  • Use smaller tags (e.g., FLAG, V5) that may cause less interference

  • Perform time-course experiments to capture dynamic localization

• Validation through functional assays:

  • Complement Δdbp7 with the tagged constructs to verify functionality

  • Analyze pre-rRNA processing in strains expressing different constructs

  • Perform polysome profiles to assess ribosome biogenesis efficiency

  • Test interactions with known partners through co-immunoprecipitation

How can DBP7 antibodies be used to investigate the relationship between ribosome biogenesis and cellular stress responses?

DBP7 antibodies can help elucidate the connection between ribosome assembly and stress pathways:

Methodological approaches:

• Stress-induced changes in DBP7 complexes:

  • Subject cells to different stresses (nutrient deprivation, oxidative stress, heat shock)

  • Immunoprecipitate DBP7 complexes before and after stress

  • Analyze changes in associated proteins and RNAs

  • Monitor post-translational modifications of DBP7

• Ribosome quality control assessment:

  • Use DBP7 antibodies to isolate early pre-60S particles

  • Compare particle composition between normal and stress conditions

  • Analyze degradation intermediates using Northern blotting

  • Monitor recruitment of quality control factors

• Signaling pathway interactions:

  • Investigate DBP7 association with stress-responsive kinases

  • Analyze phosphorylation status of DBP7 under different conditions

  • Examine localization changes during stress responses

  • Study potential sequestration in stress granules or other compartments

Research indicates that in the absence of DBP7 or its catalytic activity, early pre-ribosomal particles are targeted for degradation . This suggests DBP7 may function as a quality control checkpoint in ribosome assembly, particularly under stress conditions that affect energy availability for ATP-dependent processes.

What approaches can be used to study evolutionary conservation of DBP7 function across different species using antibodies?

Investigating DBP7 conservation requires specialized comparative approaches:

Methodological framework:

• Cross-species reactivity testing:

  • Test commercially available antibodies against DBP7 homologs in different species

  • Perform Western blotting on extracts from various organisms

  • Optimize conditions for each species (buffer composition, extraction methods)

  • Generate new antibodies against conserved epitopes if necessary

• Comparative analysis of DBP7 complexes:

  • Immunoprecipitate DBP7 from different species

  • Compare composition of associated proteins and RNAs

  • Analyze conservation of interaction networks

  • Study functional complementation between homologs

• Heterologous expression experiments:

  • Express DBP7 homologs from different species in S. cerevisiae Δdbp7 strain

  • Use antibodies to verify expression and localization

  • Assess functional complementation through growth and ribosome biogenesis assays

  • Identify species-specific differences in DBP7 function

DBP7 homologs have been identified in various yeast species including S. cerevisiae, C. albicans, S. pombe, C. glabrata, and A. gossypii . All share the characteristic DEAD-box helicase domain but may have species-specific variations in their N- and C-terminal extensions. This diversity could reflect adaptation to specific ribosome assembly pathways across different evolutionary lineages.

How can researchers apply DBP7 antibodies to investigate the coupling between transcription and early ribosome assembly?

Studying the interface between transcription and early ribosome assembly requires specialized approaches:

Methodological strategies:

• Chromatin-associated ribosome assembly:

  • Perform chromatin immunoprecipitation (ChIP) with DBP7 antibodies

  • Analyze co-precipitation of rDNA regions

  • Combine with RNA immunoprecipitation to study nascent pre-rRNA binding

  • Perform sequential ChIP with RNA polymerase I and DBP7 antibodies

• Co-transcriptional assembly visualization:

  • Use DBP7 antibodies for immunofluorescence microscopy

  • Combine with fluorescence in situ hybridization (FISH) for nascent pre-rRNAs

  • Analyze co-localization at nucleolar organizing regions

  • Implement super-resolution microscopy for detailed spatial relationships

• Dynamic association studies:

  • Utilize chromatin fractionation to isolate transcription-associated complexes

  • Immunoprecipitate DBP7 from these fractions

  • Analyze temporal dynamics using synchronized cells or inducible systems

  • Implement live-cell imaging with fluorescent tags combined with fixed-cell antibody verification

The early association of DBP7 with 35S and 33S/32S pre-rRNA intermediates suggests it may function during or shortly after transcription . This early recruitment could be critical for establishing proper rRNA folding patterns that facilitate subsequent assembly steps, highlighting the importance of co-transcriptional ribosome assembly processes.

How might new antibody-based technologies advance our understanding of DBP7's role in ribosome biogenesis disorders?

Emerging antibody technologies offer promising approaches for studying DBP7 in disease contexts:

Innovative methodological approaches:

• Single-cell analysis technologies:

  • Develop antibody-based methods for single-cell DBP7 detection

  • Implement mass cytometry (CyTOF) with DBP7 antibodies

  • Apply spatial transcriptomics with DBP7 protein detection

  • Correlate DBP7 levels with ribosome biogenesis markers at single-cell resolution

• Proximity labeling applications:

  • Express DBP7 fused to BioID or APEX2

  • Identify proteins in proximity to DBP7 through streptavidin pulldown

  • Compare proximity maps between normal and disease conditions

  • Combine with antibody-based validation of identified interactions

• Therapeutic targeting approaches:

  • Develop antibody-drug conjugates targeting aberrant DBP7 activity

  • Generate intrabodies to modulate DBP7 function in specific compartments

  • Create degrader technologies (PROTACs) guided by DBP7 antibodies

  • Design antibody-based diagnostic tools for ribosome biogenesis disorders

While current research focuses on basic mechanisms of DBP7 function in model organisms , future applications could extend to human ribosome biogenesis disorders, which are increasingly recognized as a cause of various diseases including ribosomopathies and certain cancers. Understanding the precise role of DEAD-box helicases like DBP7 in these contexts could open new avenues for diagnosis and treatment.

What new experimental approaches could combine DBP7 antibodies with structural biology techniques?

Integration of antibody-based methods with structural techniques offers powerful new research opportunities:

Advanced methodological integration:

• Cryo-EM structural analysis:

  • Use DBP7 antibodies to isolate homogeneous pre-60S populations

  • Apply Fab fragments as fiducial markers for particle orientation

  • Identify DBP7 binding sites on pre-60S particles at near-atomic resolution

  • Compare structures with and without ATP to visualize conformational changes

• In situ structural approaches:

  • Implement proximity labeling with structure-specific crosslinkers

  • Develop DBP7-specific nanobodies for in-cell structural studies

  • Apply correlative light and electron microscopy with DBP7 antibodies

  • Use cryo-electron tomography with immunogold labeling

• Time-resolved structural analysis:

  • Isolate DBP7-containing particles at different assembly stages

  • Apply time-resolved cryo-EM approaches

  • Combine with chemical crosslinking and mass spectrometry

  • Develop computational models of dynamic DBP7-mediated remodeling

Recent advances in cryo-EM technology have revolutionized our understanding of ribosome assembly pathways. DBP7's role in early pre-60S remodeling, particularly in domain V/VI compaction , could be visualized at unprecedented resolution through these approaches, potentially revealing the molecular mechanisms underlying its ATP-dependent remodeling activity.

How can computational approaches be integrated with antibody-based experimental data to model DBP7 function in ribosome assembly?

Computational methods can enhance antibody-derived experimental data on DBP7:

Integrated computational frameworks:

• Network-based modeling:

  • Use immunoprecipitation data to build protein-protein interaction networks

  • Integrate temporal data to create dynamic models of assembly pathways

  • Apply machine learning to predict functional relationships

  • Develop mathematical models of assembly kinetics based on quantitative antibody data

• Structural prediction and simulation:

  • Model DBP7-RNA interactions based on crosslinking and immunoprecipitation data

  • Simulate ATP-dependent conformational changes

  • Predict effects of mutations on protein stability and interactions

  • Model domain movements during helicase activity

• Multi-scale integration:

  • Link molecular dynamics simulations with particle-level assembly models

  • Incorporate antibody-derived constraint data into structural predictions

  • Develop 3D models of nucleolar organization with DBP7 localization data

  • Create virtual ribosome assembly simulations constrained by experimental data

Computational approaches could help resolve seemingly contradictory experimental data, such as the different behavior of DBP7 truncation mutants in sucrose gradient versus immunoprecipitation experiments . By developing models that account for the physicochemical properties of these different experimental conditions, researchers could gain deeper insights into the true nature of DBP7's interactions with pre-ribosomal particles.